Drugs / Warfarin
Warfarin
also known as
Coumadin · Warfarin Sodium · Marevan · acecoumaril · Aldocumar · Apo-warfarin · Athrombin · Athrombin-k · +22 more
Small molecule targets VKORC1
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | COUMADIN | — | 1994-03-31 – 1995-04-28 | fda.gov ↗ |
| Approved | US (FDA) | COUMADIN | — | 1954-06-08 | fda.gov ↗ |
Trials 229 · started per year
today
US approved 1954
1
1
1
2
4
3
5
6
1
6
11
9
8
11
14
11
5
6
8
19
12
11
12
7
9
7
6
10
8
9
6
195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
Also used as a comparator or background therapy in 205 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06615596 Comparator | Aug 2025 → Jan 2029 expected | atrial fibrillation | China National Center for Cardiovascular Diseases | Recruiting | No outcome recorded |
| Phase 0 | NCT06145269 Comparator | Dec 2023 → Apr 2025 | venous thromboembolism | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT02331095 Background | Jan 2015 → Oct 2017 | venous thromboembolism | Ohio State University | Terminated | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT03347968 Comparator | Nov 2017 → Apr 2018 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT01518231 Comparator | Jan → Dec 2012 | stroke disorder | Zhejiang Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT01133366 Comparator | May 2010 | — | Kastle Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00904176 Comparator | Jun → Aug 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01507051 Background | Nov 2008 → Nov 2009 | venous thromboembolism | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01042704 Background | Feb 2008 → Jan 2011 | plasma cell myeloma | Robert Redner, MD | Completed | No outcome recorded |
| Phase 1 | NCT00533026 Comparator | Jul → Oct 2007 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00487136 Comparator | Jun → Jul 2007 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01561937 Background | Jan 2007 → Jul 2008 | vascular hemostatic disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00001713 Background | Feb 1998 → Jan 2006 | thrombophlebitis | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03747081 Comparator | Sep 2018 → Jan 2020 | cerebral sinovenous thrombosis | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT00790842 Background | Jan 2009 → Sep 2017 | plasma cell myeloma | PrECOG, LLC. | Terminated | No outcome recorded |
| Phase 233 trials | ||||||
| Phase 2 | NCT05006287 Comparator | Oct 2022 → May 2024 | atrial fibrillation | St. Paul's Hospital, Canada | Unknown | No outcome recorded |
| Phase 2 | NCT05540587 Comparator | May 2022 → May 2024 | atrial fibrillation, mitral valve stenosis, stroke disorder | Sung-Hwan Kim | Unknown | No outcome recorded |
| Phase 2 | NCT04002011 Comparator | Mar 2022 → Jan 2023 | bleeding disorder, vascular-type | Laval University | Withdrawn | No outcome recorded |
| Phase 2 | NCT04865978 Comparator | Dec 2021 → Oct 2023 | heart failure | Palak Shah | Completed | No outcome recorded |
| Phase 2 | NCT03684564 Comparator | Jul 2021 → Jul 2025 | antiphospholipid syndrome, brain ischemia, ischemic stroke, systemic lupus erythematosus | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT02981472 Comparator | Jan 2017 → Oct 2021 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02303795 Comparator | Aug 2015 → Aug 2020 | heart valve disorder | Hospital do Coracao | Completed | No outcome recorded |
| Phase 2 | NCT02492230 Comparator | May 2015 → Mar 2016 | myocardial infarction | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT02238535 Comparator | Sep 2014 → Mar 2016 | pulmonary hypertension | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT02042534 Comparator | Jan 2014 → Dec 2015 | transient ischemic attack | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01662908 Comparator | Aug 2012 → Jan 2014 | venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT01695824 Comparator | Dec 2011 → Nov 2014 | atrial fibrillation | Meshalkin Research Institute of Pathology of Circulation | Completed | No outcome recorded |
| Phase 2 | NCT01505881 Comparator | Dec 2011 → Jun 2013 | cardiac valvular defect, thrombotic disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT01452347 Comparator | Oct 2011 → Jun 2013 | heart valve disorder | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT01391962 Background | Jul 2011 → Nov 2023 | alveolar soft part sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01036802 Comparator | Dec 2009 → Sep 2012 | pulmonary hypertension | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT00938730 Comparator | Jun 2009 → Sep 2010 | atrial fibrillation | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00742859 Comparator | Oct 2008 → Aug 2009 | atrial fibrillation | Portola Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00787150 Comparator | Jun 2008 → Sep 2009 | atrial fibrillation | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00595426 Comparator | May 2008 → May 2009 | osteoarthritis, knee | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00673439 Background | Nov 2007 → Sep 2011 | heparin-induced thrombocytopenia | University of Louisville | Terminated | No outcome recorded |
| Phase 2 | NCT00806624 Comparator | Oct 2007 → Oct 2008 | atrial fibrillation, stroke disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00645853 Comparator | Oct 2007 → May 2009 | persistent atrial fibrillation | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00504556 Comparator | Jun 2007 → Jun 2008 | atrial fibrillation, thrombotic disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00448214 Comparator | Mar 2007 → Oct 2008 | atrial fibrillation | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00829933 Comparator | Mar 2007 → Jul 2008 | atrial fibrillation | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00356759 Comparator | Dec 2006 → Jan 2010 | atrial fibrillation, heart valve disorder, venous thromboembolism | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00450008 Background | Dec 2006 → Aug 2008 | prostate neoplasm | The Methodist Hospital Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00814177 Comparator | Jul 2006 → Jan 2009 | atrial fibrillation, ischemic stroke, myocardial infarction, venous thromboembolism | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00973245 Comparator | Jul 2006 → Jan 2007 | atrial fibrillation | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01136408 Comparator | Nov 2005 → Sep 2006 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00973323 Comparator | Sep 2005 → Mar 2006 | atrial fibrillation | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01227629 Comparator | Sep 2003 → Nov 2004 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT03566303 Comparator | Jul 2018 → Apr 2020 | blood coagulation disease, heart valve disorder, stroke disorder | Hospital Geral Roberto Santos | Terminated | No outcome recorded |
| Phase 2/3 | NCT02889562 Comparator | Sep 2016 → May 2019 | atrial fibrillation, stroke disorder, venous thromboembolism | Sanford Health | Completed | No outcome recorded |
| Phase 2/3 | NCT01868243 Comparator | Aug 2013 → Sep 2014 | — | Hospital Ana Nery | Terminated | No outcome recorded |
| Phase 2/3 | NCT00927862 Comparator | Aug 2008 → Dec 2010 | thrombotic disease | Intermountain Health Care, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00691470 Comparator | May 2008 → Jun 2009 | atrial fibrillation, atrial flutter, cardiomyopathy, myocardial infarction +1 | ARYx Therapeutics | Unknown | No outcome recorded |
| Phase 2/3 | NCT00129545 Comparator | Feb 2005 → Aug 2013 | atrial fibrillation, stroke disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT00097357 Comparator | Oct 2004 → Dec 2005 | pulmonary embolism, venous thromboembolism | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 365 trials | ||||||
| Phase 3 | NCT07709780 Comparator | Jun 2026 → Jul 2028 expected | thrombotic disease | University of Arizona | Recruiting | No outcome recorded |
| Phase 3 | NCT07471139 Comparator | Jun 2026 → Jun 2029 expected | heart failure, hemorrhagic disease, stroke disorder, thrombotic disease | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07434661 Comparator | Feb 2026 → Jan 2028 expected | aortic valve disorder, atrial fibrillation, cardiac valvular defect | Meshalkin Research Institute of Pathology of Circulation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07456085 Comparator | Nov 2025 → Apr 2027 expected | heart valve disorder | Rawalpindi Institute of Cardiology | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05825573 Comparator | May 2023 → Feb 2025 overdue | ST-elevation myocardial infarction, heart failure, thrombotic disease | Nîmes University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04727437 Comparator | Apr 2021 → Jul 2023 | pulmonary embolism | University of Birmingham | Unknown | No outcome recorded |
| Phase 3 | NCT04730037 Comparator | Mar 2021 → Mar 2023 | chronic thromboembolic pulmonary hypertension | Kyushu University | Completed | No outcome recorded |
| Phase 3 | NCT05705089 Comparator | Jul 2020 → Feb 2023 | ST-elevation myocardial infarction, thrombotic disease | Rajaie Cardiovascular Medical and Research Center | Completed | No outcome recorded |
| Phase 3 | NCT04067505 Comparator | May 2020 → Dec 2024 | May-Thurner syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT04066764 Comparator | May 2020 → Oct 2024 | venous thromboembolism | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT04142658 Comparator | May 2020 → Dec 2022 | aortic valve stenosis | Artivion Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03926156 Comparator | May 2019 → May 2021 | atrial fibrillation, mitral valve stenosis, rheumatic heart disease | Rajaie Cardiovascular Medical and Research Center | Terminated | No outcome recorded |
| Phase 3 | NCT03702582 Comparator | Apr 2019 → Oct 2023 | atrial fibrillation, hemorrhagic disease, stroke disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03839355 Comparator | Dec 2018 → Dec 2020 | atrial fibrillation | Mayo Clinic | Terminated | No outcome recorded |
| Phase 3 | NCT03926780 Comparator | Dec 2018 → May 2020 | hyperheparinemia, thrombotic disease | The Young Investigator Group of Cardiovascular Research | Completed | No outcome recorded |
| Phase 3 | NCT02522221 Comparator | Jun 2018 → Mar 2019 | thrombotic disease | Espero Biopharma | Unknown | No outcome recorded |
| Phase 3 | NCT03395639 Comparator | May 2018 → Dec 2021 | heart disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT05208398 Comparator | Feb 2018 → Sep 2021 | thrombotic disease | Saud Al Babtain Cardiac Center | Completed | No outcome recorded |
| Phase 3 | NCT03232398 Comparator | Jan 2018 → Mar 2021 | acute myocardial infarction, thrombotic disease | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 3 | NCT03244319 Comparator | Dec 2017 → Sep 2019 | cardiac valvular defect | Yonsei University | Completed | No outcome recorded |
| Phase 3 | NCT03217448 Comparator | Oct 2017 → Jan 2019 | cerebral sinovenous thrombosis | Capital Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04569279 Comparator | Sep 2017 → Mar 2020 | cerebral sinovenous thrombosis | Damascus University | Completed | No outcome recorded |
| Phase 3 | NCT03181386 Comparator | May 2017 → Nov 2020 | atrial fibrillation, hemorrhagic disease, periodontal disorder | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02942576 Comparator | Mar 2017 → Sep 2018 | atrial fibrillation | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT02913326 Comparator | Dec 2016 → Jun 2018 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02982590 Comparator | Nov 2016 → Nov 2018 | thrombotic disease | Universiti Sains Malaysia | Completed | No outcome recorded |
| Phase 3 | NCT02832544 Comparator | Aug 2016 → Aug 2022 | rheumatic heart disease | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02544932 Comparator | Oct 2015 → Sep 2017 | atrial fibrillation | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02853526 Background | Jul 2015 → Dec 2017 | cirrhosis of liver, esophageal varices with bleeding, portal vein thrombosis, portal vein, cavernous transformation of | Zaibo Jiang | Unknown | No outcome recorded |
| Phase 3 | NCT02283294 Comparator | Apr 2015 → Jun 2019 | atrial fibrillation, transient ischemic attack | University of South Florida | Completed | No outcome recorded |
| Phase 3 | NCT02164864 Comparator | Jul 2014 → Jun 2017 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02072434 Comparator | Mar 2014 → Feb 2016 | atrial fibrillation | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02046460 Comparator | Sep 2013 → Jun 2019 | cervical artery dissection | Stefan Engelter | Completed | No outcome recorded |
| Phase 3 | NCT01924065 Comparator | Aug 2013 → Aug 2017 | atrial fibrillation, stroke disorder | Suleyman Demirel University | Completed | No outcome recorded |
| Phase 3 | NCT01780987 Comparator | Jan 2013 → Sep 2014 | pulmonary embolism, venous thromboembolism | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01674647 Comparator | Oct 2012 → Jan 2014 | atrial fibrillation | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01516840 Comparator | Mar 2012 → Dec 2013 | venous thromboembolism | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01516814 Comparator | Feb 2012 → Oct 2013 | pulmonary embolism | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01182441 Comparator | Nov 2010 → Jan 2013 | atrial fibrillation, stroke disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01130025 Comparator | Aug 2010 → Apr 2014 | venous thromboembolism | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01164046 Comparator | Aug 2010 → Jul 2014 | neoplasm, venous thromboembolism | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 3 | NCT01758640 Comparator | Feb 2010 → Jun 2012 | — | Yasser Elnahas | Completed | No outcome recorded |
| Phase 3 | NCT01006876 Comparator | Jan 2010 → Mar 2013 | thrombotic disease | Texas Cardiac Arrhythmia Research Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00957242 Comparator | Oct 2009 → Jul 2011 | idiopathic pulmonary fibrosis | Duke University | Terminated | No outcome recorded |
| Phase 3 | NCT00986154 Comparator | Oct 2009 → Apr 2013 | pulmonary embolism, thrombotic disease, venous thromboembolism | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00781391 Comparator | Nov 2008 → Apr 2013 | atrial fibrillation, stroke disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00643201 Comparator | Jul 2008 → Mar 2013 | venous thromboembolism | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00680186 Comparator | Apr 2008 → May 2011 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00895505 Comparator | Feb 2008 → Feb 2012 | venous thromboembolism | University Hospital, Bonn | Unknown | No outcome recorded |
| Phase 3 | NCT00740883 Comparator | Jul 2007 → Oct 2015 | pulmonary embolism | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT00740493 Comparator | Jul 2007 → Jan 2017 | venous thromboembolism | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT00494871 Comparator | Jun 2007 → Dec 2009 | atrial fibrillation | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00440193 Comparator | Mar 2007 → Apr 2010 | venous thromboembolism | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00412984 Comparator | Dec 2006 → May 2011 | atrial fibrillation, atrial flutter | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00403767 Comparator | Dec 2006 → Sep 2010 | atrial fibrillation, stroke disorder | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00329238 Comparator | May 2006 → Oct 2010 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00291330 Comparator | Feb 2006 → May 2009 | venous thromboembolism | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00262600 Comparator | Dec 2005 → Apr 2009 | atrial fibrillation, stroke disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00238667 Comparator | Nov 2005 → May 2014 | carotid artery dissection, stroke disorder, vertebral artery dissection | St George's, University of London | Completed | No outcome recorded |
| Phase 3 | NCT00041938 Comparator | Oct 2002 → Aug 2011 | myocardial infarction, myocardial ischemia, stroke disorder | Columbia University | Completed | No outcome recorded |
| Phase 3 | NCT00235248 Comparator | Feb 2002 → Dec 2010 | brain infarction, transient ischemic attack | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00004054 Background | Jan 2000 → Apr 2010 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00157651 Comparator | Feb 1999 → Mar 2007 | end stage renal failure, hemorrhagic disease, thrombotic disease | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00007683 Comparator | Oct 1998 → Jul 2003 | heart failure | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 3 | NCT00027066 Comparator | Jun 1993 → Jun 2000 | stroke disorder | Columbia University | Completed | No outcome recorded |
| Phase 460 trials | ||||||
| Phase 4 | NCT07644247 Background | Jun 2026 → Jan 2029 expected | hemorrhagic disease, left ventricular failure, stroke disorder, thrombotic disease | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07431762 Comparator | Jun 2026 → Oct 2030 expected | cardiac valvular defect | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07352358 Background | Jan 2026 → Jul 2028 expected | cerebral sinovenous thrombosis | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 4 | NCT05643651 Comparator | Jun 2025 → Jun 2027 expected | Kawasaki disease, coronary aneurysm | Children's Hospital of Fudan University | Recruiting | No outcome recorded |
| Phase 4 | NCT06515730 Comparator | Apr 2025 → Apr 2028 expected | acute myocardial infarction, thrombotic disease | Karolinska Institutet | Recruiting | No outcome recorded |
| Phase 4 | NCT06738992 Comparator | Nov 2024 → Dec 2027 expected | — | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06655376 Background | Oct 2024 → Apr 2027 expected | hemorrhagic disease, thrombotic disease | Columbia University | Recruiting | No outcome recorded |
| Phase 4 | NCT05995600 Comparator | Feb 2024 → Mar 2029 expected | antiphospholipid syndrome, transient ischemic attack | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07404436 Comparator | Jan 2024 → Dec 2026 expected | idiopathic membranous glomerulonephritis | Beijing Friendship Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05794399 Comparator | Jun 2023 → Mar 2026 overdue | myocardial infarction, thrombotic disease | Shahid Gangalal National Heart Centre | Recruiting | No outcome recorded |
| Phase 4 | NCT05973188 Comparator | May 2023 → Jun 2024 | thrombotic disease | Peshawar Institute of Cardiology | Unknown | No outcome recorded |
| Phase 4 | NCT04258488 Comparator | Feb 2022 → Dec 2027 expected | aortic valve disorder, thrombotic disease | Joon Bum Kim | Recruiting | No outcome recorded |
| Phase 4 | NCT05122780 Comparator | Jul 2021 → Jul 2025 overdue | myocardial infarction | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04970576 Comparator | Jun 2021 → May 2024 | acute coronary syndrome, thrombotic disease | National Institute of Cardiovascular Diseases, Pakistan | Completed | No outcome recorded |
| Phase 4 | NCT04045093 Comparator | Oct 2020 → Sep 2026 expected | atrial fibrillation, mitral valve stenosis | The University of Hong Kong | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04250116 Background | Apr 2020 → Apr 2025 overdue | atrial fibrillation | Yonsei University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04073316 Comparator | Feb 2020 → Feb 2023 | atrial fibrillation | University Hospital, Angers | Unknown | No outcome recorded |
| Phase 4 | NCT03862859 Comparator | Oct 2019 → Jan 2027 expected | atrial fibrillation, end stage renal failure, stroke disorder | Nicholas Carlson | Recruiting | No outcome recorded |
| Phase 4 | NCT03866681 Background | Apr 2019 → Mar 2021 | paroxysmal nocturnal hemoglobinuria | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03536611 Comparator | Sep 2018 → Dec 2019 | atrial fibrillation, coronary artery disorder | Shenyang Northern Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03196349 Comparator | Aug 2018 → May 2019 | venous thromboembolism | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT03490994 Comparator | Apr 2018 → Sep 2019 | heart failure | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT03463317 Comparator | Feb 2018 → Nov 2024 | atrial fibrillation | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT03062319 Comparator | Apr 2017 → Jul 2023 | atherosclerosis, atrial fibrillation, ischemic stroke | National Hospital Organization Osaka National Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT03061006 Comparator | Mar 2017 → Mar 2021 | brain ischemia, dementia | Intermountain Health Care, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03088072 Background | Mar 2017 → Nov 2018 | atrial fibrillation | Scripps Health | Unknown | No outcome recorded |
| Phase 4 | NCT03673605 Comparator | Dec 2016 → Oct 2017 | atrial fibrillation, mitral valve stenosis | PharmEvo Pvt Ltd | Withdrawn | No outcome recorded |
| Phase 4 | NCT02982850 Comparator | Dec 2016 → Oct 2020 | atrial fibrillation, heart valve disorder | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02836652 Background | Nov 2016 → Feb 2019 | heart failure | Abbott Medical Devices | Completed | No outcome recorded |
| Phase 4 | NCT02979561 Comparator | Oct 2016 → Jun 2018 | — | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 4 | NCT03183843 Comparator | Jun 2016 → Jun 2018 | atrial fibrillation, heart valve disorder | Research Institute for Complex Problems of Cardiovascular Diseases, Russia | Unknown | No outcome recorded |
| Phase 4 | NCT02701062 Background | Feb 2016 → Apr 2019 | atrial fibrillation | AtriCure, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02561897 Comparator | Dec 2015 → Sep 2017 | atrial fibrillation | Electrophysiology Research Foundation | Terminated | No outcome recorded |
| Phase 4 | NCT02452918 Background | Sep 2015 → Jul 2016 | — | The Medicines Company | Completed | No outcome recorded |
| Phase 4 | NCT02935855 Comparator | Sep 2015 → Apr 2019 | diabetes mellitus | University of Pavia | Completed | No outcome recorded |
| Phase 4 | NCT02348723 Comparator | Apr 2015 → Nov 2016 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02376010 Comparator | Apr 2015 → Apr 2018 | atherosclerosis | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02295475 Comparator | Dec 2014 → Apr 2020 | antiphospholipid syndrome, thrombotic disease | Scott C. Woller, MD | Completed | No outcome recorded |
| Phase 4 | NCT02227550 Comparator | Dec 2014 → Apr 2017 | atrial fibrillation | Atrial Fibrillation Network | Completed | No outcome recorded |
| Phase 4 | NCT01994265 Comparator | Nov 2014 → Mar 2021 | atrial fibrillation | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02303171 Comparator | Nov 2014 → Dec 2024 | antiphospholipid syndrome, pregnancy loss, recurrent, 4 | Mohamed Sayed Abdelhafez | Unknown | No outcome recorded |
| Phase 4 | NCT02206815 Comparator | Sep 2014 → Feb 2019 | atrial fibrillation, coronary artery disorder | Genshan Ma | Completed | No outcome recorded |
| Phase 4 | NCT02090075 Comparator | Sep 2014 → Dec 2016 | atrial fibrillation | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02100228 Comparator | Jul 2014 → Feb 2017 | atrial fibrillation | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02054936 Comparator | Mar 2014 → Feb 2016 | — | University of Michigan | Withdrawn | No outcome recorded |
| Phase 4 | NCT02024230 Comparator | Jan 2014 → Dec 2018 | atrial fibrillation, coronary artery disorder, stroke disorder | Fujita Health University | Completed | No outcome recorded |
| Phase 4 | NCT01962545 Background | Nov 2013 → May 2017 | atrial fibrillation, coronary artery disorder | Satoshi Shizuta | Completed | No outcome recorded |
| Phase 4 | NCT02334254 Comparator | Aug 2013 → Jan 2016 | atrial fibrillation | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02022527 Background | Jun 2013 → Jul 2014 | cardiac valvular defect | Pharmacoeconomic Unit, Egypt | Unknown | No outcome recorded |
| Phase 4 | NCT02161965 Comparator | May 2013 → Dec 2016 | atrial fibrillation, pulmonary embolism, venous thromboembolism | University Hospital, Angers | Completed | No outcome recorded |
| Phase 4 | NCT01747746 Background | Oct 2012 → Oct 2014 | atrial fibrillation, hemorrhagic disease, stroke disorder, venous thromboembolism | Cook County Health | Completed | No outcome recorded |
| Phase 4 | NCT01727453 Comparator | Dec 2011 → Sep 2015 | — | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00993200 Comparator | Aug 2009 → Dec 2010 | thrombotic disease | Robert Pendleton | Completed | No outcome recorded |
| Phase 4 | NCT01569035 Comparator | Jan 2009 → Jul 2011 | oligohydramnios | Woman's Health University Hospital, Egypt | Terminated | No outcome recorded |
| Phase 4 | NCT00559988 Background | Feb 2008 → Jun 2013 | arterial occlusion, atrial fibrillation, atrial flutter, stroke disorder | Biotronik, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT01452568 Comparator | Jun 2005 → Mar 2012 | hemorrhagic disease, thrombotic disease | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00164112 Background | Nov 2004 → Jun 2005 | — | Bassett Healthcare | Completed | No outcome recorded |
| Phase 4 | NCT00966290 Comparator | Feb 2003 → Dec 2006 | blood coagulation disease | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT00623987 Comparator | Jun 1999 → Jun 2006 | venous thromboembolism | Azienda Ospedaliera Universitaria Policlinico | Completed | No outcome recorded |
| Phase 4 | NCT00697151 Comparator | Jun 1993 → Jun 2000 | ischemic stroke, patent foramen ovale | Columbia University | Completed | No outcome recorded |
| Phase not applicable25 trials | ||||||
| — | NCT07677410 Comparator | Jul 2026 → Jul 2029 expected | aortic valve insufficiency | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07548346 Background | Jul 2026 → Jan 2029 expected | cerebral sinovenous thrombosis | Middle East North Africa Stroke and Interventional Neurotherapies Organization | Not yet recruiting | No outcome recorded |
| — | NCT04684212 Comparator | Jun 2024 | atrial fibrillation, stroke disorder | Brian O'Neill MD | Withdrawn | No outcome recorded |
| — | NCT06055920 Comparator | Nov 2023 → Jul 2026 overdue | pulmonary embolism | Inari Medical | Active not recruiting | No outcome recorded |
| — | NCT05701917 Comparator | Jan 2023 → Jun 2026 overdue | post-thrombotic syndrome, venous thromboembolism | Inari Medical | Recruiting | No outcome recorded |
| — | NCT05622500 Background | Sep 2022 → Apr 2025 | chronic venous insufficiency, post-thrombotic syndrome | Imperial College London | Terminated | No outcome recorded |
| — | NCT06449469 Background | May 2021 → Apr 2026 overdue | aortic valve stenosis | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| — | NCT04855110 Comparator | Apr 2021 → Mar 2022 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT03896321 Comparator | Dec 2019 → Dec 2021 | coronary artery disorder | Assiut University | Completed | No outcome recorded |
| — | NCT03792152 Comparator | Jun 2019 → Jan 2022 | atrial fibrillation | The Second Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
| — | NCT04121767 Comparator | Dec 2017 → Jun 2020 | atrial fibrillation, blood coagulation disease | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT03191305 Comparator | Aug 2017 → Sep 2018 | cerebral sinovenous thrombosis | Foundation University Islamabad | Unknown | No outcome recorded |
| — | NCT02485184 Comparator | Jul 2017 → Dec 2024 | cirrhosis of liver, portal vein thrombosis | Air Force Military Medical University, China | Unknown | No outcome recorded |
| — | NCT03465735 Background | Jan 2017 → Aug 2019 | venous thromboembolism | Mayo Clinic | Terminated | No outcome recorded |
| — | NCT02744092 Comparator | Dec 2016 → Oct 2020 | cancer, pulmonary embolism, thrombotic disease, venous thromboembolism | Alliance Foundation Trials, LLC. | Completed | No outcome recorded |
| — | NCT02704598 Comparator | Mar 2016 → Dec 2018 | venous thromboembolism | Hospital do Servidor Publico Estadual | Unknown | No outcome recorded |
| — | NCT02392104 Background | Mar 2015 → Jun 2017 | — | William S. Middleton Memorial Veterans Hospital | Completed | No outcome recorded |
| — | NCT01953874 Background | Dec 2013 → Dec 2015 | heart failure, sleep apnea syndrome | ResMed | Terminated | No outcome recorded |
| — | NCT01986192 Comparator | Nov 2013 → Feb 2015 | venous thromboembolism | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT02240927 Comparator | Jan 2010 → Jun 2015 | cardiac valvular defect, pregnancy disorder | Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital | Unknown | No outcome recorded |
| — | NCT02240953 Comparator | Jan 2009 → Dec 2014 | thrombotic disease | Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital | Unknown | No outcome recorded |
| — | NCT00767559 Comparator | Nov 2008 → Oct 2011 | pulmonary embolism | The New England Baptist Hospital | Unknown | No outcome recorded |
| — | NCT01034124 Comparator | Jan → Nov 2007 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT00870298 Background | Aug 2006 → Jan 2007 | — | University of Pennsylvania | Terminated | No outcome recorded |
| — | NCT00621491 Comparator | Feb 2004 → Sep 2007 | venous thromboembolism | University of Sao Paulo | Completed | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-20 | Amgen | AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS amgen.com ↗ |
| 2017-09-13 | AbbVie | AbbVie Announces 25th Annual Cystic Fibrosis Scholarship Program Including 2017 Thriving Student Scholarship Contest and Blogger's Choice Award abbvie.com ↗ |
| 2017-08-29 | Pfizer | Bristol-Myers Squibb and Pfizer Alliance Announce Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Elderly Patients with Non-Valvular Atrial Fibrillation pfizer.com ↗ |
| 2017-08-27 | Pfizer | Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvular Atrial Fibrillation pfizer.com ↗ |
| 2017-03-17 | Pfizer | Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation pfizer.com ↗ |
| 2013-12-10 | Daiichi Sankyo | Phase 3 Data Show Daiichi Sankyo’s Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer daiichisankyo.com ↗ |
| 2013-11-20 | Daiichi Sankyo | Daiichi Sankyo´s Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial daiichisankyo.com ↗ |
| 2013-09-01 | Daiichi Sankyo | Daiichi Sankyo’s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence daiichisankyo.com ↗ |
| 2008-12-08 | Daiichi Sankyo | NEW PHASE II DATA SHOW SAFETY OF ONCE-DAILY ORAL FACTOR Xa INHIBITOR, DU-176b, COMPARABLE TO WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION daiichisankyo.com ↗ |
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 436 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | warfarin | “After discharge, these patients were switched to oral low-dose warfarin for anticoagulation, with a daily dose of 1.25mg (half tablet) on dialysis days, and 2.5mg/day on...” NCT04164693 ↗416“Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles.” NCT06615596 ↗ “Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.” NCT02592317 ↗ “Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)” NCT03234114 ↗ “followed by oral anticoagulation with warfarin (target INR 2.0-3.0) or direct oral anticoagulants (DOACs) for 3-12 months as per current AHA/ASA and ESO guidelines.” NCT07548346 ↗ “Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.” NCT05622500 ↗ “Single dose of drug cocktail: 100 milligram (mg) caffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 1 in Period 1.” NCT02688088 ↗ “Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.” NCT02017197 ↗ “subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT” PMID 21128814 ↗ Dec 2010 “the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards” NCT01674647 ↗ “Co-administered drugs include: - Warfarin - 10 mg tablets, midazolam 1 mg, digoxin 0.25 mg, rosuvastatin 10 mg, omeprazole 20 mg, Vitamin K - 10 mg.” NCT06975605 ↗ “Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated” NCT01953874 ↗ “Based on the significant flow disturbances within the ectatic segments, chronic anticoagulation with warfarin as main therapy was suggested” NCT03896321 ↗ “VKA study medications (Warfarin, Fluindione and Acenocoumarol) will be prescribed and supplied in the usual setting of patient care” NCT05825573 ↗ “Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.” NCT02331095 ↗ “probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).” NCT00401583 ↗ “Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution” NCT02623296 ↗ “Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg” NCT04233437 ↗ “AIM: To determine the efficacy and safety of warfarin resumption with loading doses or with the most recent maintenance dose.” PMID 24837794 ↗ Jun 2014 “Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally” NCT03718884 ↗ “Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20” NCT01001299 ↗ “Low-molecular-weight heparin bridging to warfarin 3 mg/day, rivaroxaban 10-20 mg/day or dabigatran 110-150 mg twice daily.” NCT07352358 ↗ “i.e. warfarin; the selection of the anticoagulant agent will be based on the clinical scenario, contraindications etc” NCT05122780 ↗ “Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.” NCT06402851 ↗ “oral dose of the Cooperstown Cocktail (midazolam, omeprazole, warfarin, caffeine, and dextromethorphan)” NCT02434861 ↗ “Warfarin was administered orally at a dose of 1mg per day for a year,then gradually reduced to stop.” NCT03866681 ↗ “treated with vitamin K antagonists (either warfarin or acenocoumarol) for a minimum of 3 months” NCT00264277 ↗ “Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis” NCT03191305 ↗ “customizing a popular blood thinner (warfarin) to each person's genetic and clinical profile” NCT01006733 ↗ “Warfarin for 6 months followed by antiplatelet agents is recommended as medical treatment.” PMID 21356042 ↗ Feb 2011 “warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur.” NCT03764241 ↗ “BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)” NCT03561298 ↗ “Warfarin and midazolam will be co-administered alone and in combination with ZSP1273.” NCT05942365 ↗ “Warfarin (10 mg + 10 mg vitamin K orally) with collection of plasma over 96 hours.” NCT00164112 ↗ “Caffeine + Warfarin (plus vitamin K) + Omeprazole + Dextromethorphan + Midazolam” NCT02993471 ↗ “OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA” NCT00559988 ↗ “Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban” NCT06401616 ↗ “15 mg single dose of warfarin (oral tablet) will be given to patients.” NCT01769768 ↗ “warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage” NCT01924065 ↗ “To demonstrate that apixaban is safer than warfarin at 1 year” PMID 39306346 ↗ Sep 2024 “CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19” PMID 39707077 ↗ Dec 2024 “Warfarin is allowed to use at the physicians' discretion.” NCT04250116 ↗ “aspirin (325 mg daily) and/or warfarin (target INR = 2.5)” NCT00201461 ↗ “aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)” NCT03415386 ↗ “warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban” NCT03062319 ↗ “Anticoagulation therapy includes heparin and warfarin.” NCT02485184 ↗ “We included two patient cohorts treated with warfarin” PMID 26050796 ↗ Jun 2015 “An example of this type is Warfarin (Coumadin).” NCT02100228 ↗ “Vitamin K antagonists (e.g warfarin)+/- LDA” NCT07658989 ↗ “warfarin and novel oral anticoagulants” NCT03126214 ↗ “Dose adjusted Coumadin (warfarin)” NCT00691470 ↗ “Vitamin-K antagonists (warfarin)” NCT05375474 ↗ “OAC includes warfarin or NOAC.” NCT01962545 ↗ “Warfarin (Coumadin, Jantoven)” NCT03465735 ↗ “Warfarin/Coumadin” NCT02701062 ↗ “Warfarin/heparin” NCT03395639 ↗ “Warfarin/heparin” NCT02798471 ↗ “Drug: Warfarin” NCT01636557 ↗ “warfarin” NCT01164046 ↗ “warfarin” NCT04907825 ↗ “Warfarin” NCT07011095 ↗ “Warfarin” NCT02981472 ↗ “Warfarin” NCT02942576 ↗ “warfarin” NCT00645853 ↗ |
| Known as | acecoumaril | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02227550 ↗ |
| Known as | Aldocumar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Apo-warfarin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Athrombin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Athrombin-k | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Choice | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Coumadin | “Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)” NCT04684212 ↗21“Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration.” NCT00450008 ↗ “Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.” NCT06055920 ↗ “If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.” NCT01042704 ↗ “Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.” NCT00790842 ↗ “the FDA approved the label change of warfarin/Coumadin™ to recommend considering lower initial doses” NCT01006733 ↗ “Warfarin (also called Coumadin®) is an anticoagulant drug (blood thinner)” NCT00377143 ↗ “an anticoagulation medicine called warfarin (Coumadin®)” NCT00634907 ↗ “warfarin (Coumadin, Bristol Myers Squibb) for 3 months” NCT00438230 ↗ “An example of this type is Warfarin (Coumadin).” NCT02100228 ↗ “Warfarin (Coumadine): INR target \[2.0-3.0\]” NCT06045858 ↗ “warfarin (Coumadin, Bristol Myers Squibb)” NCT00623987 ↗ “Drug: Warfarin (Coumadin)” NCT01507051 ↗ “Warfarin or coumadin” NCT00800137 ↗ “Warfarin (Coumadin)” NCT02054936 ↗ |
| Known as | Coumadine | “Warfarin (Coumadine): INR target \[2.0-3.0\]” NCT06045858 ↗ |
| Known as | Jantoven | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Marevan | “If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral...” NCT06449469 ↗2“We aim to determine, through mean INR difference between formulations, whether there is therapeutic equivalency between the branded warfarin sodium (Marevan®) and the generic...” NCT02017197 ↗ “comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)” NCT06145269 ↗ |
| Known as | NSC-59813 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Orfarin | “Warfarin (Orfarin®) is the most popular vitamin K antagonist” NCT04569279 ↗ |
| Known as | Panwarfin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Potassium warfarin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Prothromadin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Sodium warfarin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01285661 ↗ |
| Known as | Varfine | “Varfine® 5 mg (warfarin 5 mg) tablets” NCT02779348 ↗ |
| Known as | Vitamin K antagonists (VKA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02832544 ↗ |
| Known as | Vitamin-K antagonist at INR 2-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00684307 ↗ |
| Known as | Warfarin (Coumadin, Jantoven) | “Warfarin (Coumadin, Jantoven)” NCT03465735 ↗ |
| Known as | Warfarin (Marevan) | “Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.” NCT00700895 ↗ |
| Known as | WARFARIN POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Warfarin Sodium | “CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially...” NCT04562116 ↗8“SHR0302 Tablets + probe drugs (Midazolam Maleate Tablets + Warfarin Sodium Tablets+ Omeprazole Enteric Capsules+ Repaglinide Tablets) + Vitamin K1 Tablets” NCT05392127 ↗ “Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).” NCT04709094 ↗ “two tablets of warfarin sodium (5mg)” NCT07362030 ↗ “Drug: Warfarin Sodium 5 MG” NCT04235569 ↗ |
| Known as | Warfarin sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | warfarin sodium tablets | “warfarin sodium tablets” NCT04164693 ↗ |
| Known as | Warfarin/Coumadin | “Warfarin/Coumadin” NCT02701062 ↗ |
| Known as | Warfarina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Warfarine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Warfarinum natricum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Zoocoumarin sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Action | Inhibit | “warfarin inhibits circulating clotting proteins in the blood” NCT00027066 ↗ |
| Modality | Small molecule | — CHEMBL1464 ↗ |
| Route | Oral | “oral anticoagulant therapy” NCT00000517 ↗ |
| Target | VKORC1 | “warfarin target, VKORC1” NCT02065388 ↗ |